More faithful representation of disease biology is key to identify drivers of metastasis and targets for therapeutic intervention. Xylyx Bio’s IN SITE™ Metastasis Kit incorporates native tissue bone, liver, and lung extracellular matrices to provide key features of site-specific microenvironments, allowing scientists to more accurately model cancer metastasis in common secondary sites.
Xylyx Bio offers advanced lung models to accelerate COVID-19-related drug development
Humanized IN MATRICO™ Lung Fibrosis Assay provides insight into efficacy of drug candidates consistent with clinical results, increasing predictiveness and accelerating decision making in development of drugs for lung fibrosis.
Xylyx Bio announces development of disease-specific cell culture products to accelerate anti-fibrotic drug discovery and screening
Fibrosis-specific substrates provide a disease-relevant in-vitro testing platform to inform decision-making in early-stage drug discovery. Through the development of fibrosis-specific in-vitro substrates, Xylyx Bio aims to support drug discovery and development for fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH).
Xylyx Bio joins Advanced Regenerative Manufacturing Institute (ARMI) Consortium
Xylyx Bio announced that it has joined the Advanced Regenerative Manufacturing Institute (ARMI), a public-private Manufacturing USA initiative that supports the manufacturing of engineered tissues and tissue-related technologies, with the goal to focus on accelerating the standardization and commercialization of tissue-specific extracellular matrix biomaterials for regenerative medicine and tissue engineering.
Xylyx Bio Announces Global Expansion
Xylyx Bio announced partnerships with 9 international distributors to meet growing demand. Additional distributors provide scientists working in drug screening, cancer research, 3D cell models and toxicology with the ability to improve the human relevance of in vitro cell models.
East River BioSolutions Announces Rebrand to Xylyx Bio
BROOKLYN, N.Y., Dec. 17, 2018 /PRNewswire/ — East River BioSolutions, a biotech company specializing in cell-specific extracellular matrix biomaterials, today announced its rebrand to Xylyx Bio. The Company’s proprietary platform enables scientific discovery and tissue regeneration in several multibillion-dollar markets, including cell culture and therapeutics. The comprehensive new branding underscores the Company’s focus on accelerating science for improved human health and includes a new logo and website.
The name Xylyx is derived from ‘xylo-,’ the Greek root for ‘wood,’ thus encompassing the central importance of the natural environment. The dual x’s echo the sound of ‘extracellular matrix,’ the technical name for the natural cell environment, while the lines of the x’s and y’s create a visual network that reflects the intersecting fibers of the extracellular matrix.
The Xylyx logo brings a sharp visual identity that is bold and scientific. The encircling lines are comprised of multiple intersecting elements, representing the Company’s expertise in different markets. The Company’s focus on providing the full suite of components in the extracellular microenvironment is reflected in its tagline, “The Cell Environment Company.”
“Xylyx Bio continues to offer bio-inspired products that enable the most accurate and physiologically relevant results for scientists working in cell culture, supporting cell models that are more predictive of human physiology and thus facilitating acceleration of pharmaceutical drug discovery and development,” explained Andrea Nye, Xylyx Bio President and CEO. “In addition, with deep scientific expertise in biomaterials and tissue regeneration, we are addressing multiple pressing unmet clinical needs. Our new brand better establishes the Company and its strength in the marketplace and biotech ecosystem overall.”
Dr. John O’Neill, Xylyx Bio Co-Founder and Chief Scientific Officer, continued, “As we champion the paradigm shift toward more biologically relevant platforms for cells studied outside the body and regeneration within the body, we sought a name and brand that conveys our focus on extracellular matrix as well as our mission to create and deliver effective science-based solutions for the benefit of human life and health.”
About Xylyx Bio
Xylyx Bio empowers the most actionable scientific discoveries and effective tissue regeneration through the development of cell-specific biomaterials, providing native physiological microenvironments to support cell health both inside and outside the body.
Xylyx Bio, Inc.
Andrea Nye, CEO
East River BioSolutions releases NativeCoat™ ECM substrates
BROOKLYN, New York, Nov. 27, 2018 /PRNewswire/ — East River BioSolutions announced the release of NativeCoat™ ECM – a novel line of 2D in vitro cell culture coatings comprised of native tissue-derived extracellular matrix (ECM) that enables scientists to study cells in their tissue-specific microenvironments, leading to more physiologically relevant testing and thus more accurate and actionable scientific results.
Despite numerous advances in cell culture, faithfully replicating human physiology in vitro remains a significant challenge. Current substrates fail to provide the key factors necessary for cells in vitro to maintain their normal identity and activity and thrive as they would in the body. Current top-selling products are comprised of a single biochemical component or derived from rodent tumor sources. These are either too simple to provide the biochemical factors that make up the native cellular environment and support limited cell function, or they artificially alter cell growth and function, neither of which is conducive to attaining accurate data for successful scientific outcomes.
In contrast, East River Bio’s NativeCoat™ ECM coatings provide the complete milieu of the microenvironment – the ECM specific to each tissue and cell type. NativeCoat™ ECM can be used to coat any cell culture surface, bringing the highly specific composition of the native cell environment to any in vitro setting and thus allowing scientists to improve cell attachment and viability and enhance physiologic function. NativeCoat™ ECM substrates are available for multiple cell types, including liver, lung, heart and others.
Dr. Gordana Vunjak-Novakovic, University Professor at Columbia University and Founder and Chair of the Board of East River Bio, stated: “Scientists’ ability to recreate the native microenvironment in which they study cells is key to successful biological research and drug development. Because they are derived from native tissue sources, NativeCoat™ ECM substrates provide the most physiologically relevant microenvironments possible for those seeking to study how cells behave under controllable conditions in vitro. This is an important part of the paradigm shift toward tools that allow scientists to conduct physiologically relevant research and better science overall.”
About East River BioSolutions
East River Bio enables scientific discovery and tissue regeneration via cell-specific biomaterials, providing essential microenvironments for cell health both inside and outside the body. The Company offers a suite of cell-specific products for both 2D and 3D cell culture.
East River BioSolutions, Inc.
Andrea Nye, CEO
East River BioSolutions Awarded NIH SBIR Phase I Grant
NEW YORK, Oct. 22, 2018: East River BioSolutions is proud to announce that it has been awarded a $224,566 SBIR Phase I grant from the National Heart, Lung, and Blood Institute of the National Institutes of Health (“NIH”).
The award will support further development of a fibrotic lung-specific cell culture substrate that will allow scientists to build more physiologically relevant in vitro models of idiopathic pulmonary fibrosis (IPF). IPF is a devastating, intractable, and life-threatening lung disease with over 50,000 new cases diagnosed each year, median survival of only 3–4 years, and annual mortality in the US alone of over 40,000. The only two FDA-approved drugs have limited ability to slow disease progression, and the only definitive treatment for IPF remains lung transplantation, a high-risk intervention hampered by low availability of donor organs, severe complications and high cost to the health care system. Development of effective treatments is hindered because predictive models of IPF for basic research and drug development are not available, leaving a significant need for physiologically relevant experimental in vitro tools that enable quantitative and mechanistic studies of IPF.
East River Bio will fill this gap by providing scientists and companies in need of predictive models with access to a disease-specific native tissue cell culture environment that will enable better in vitro models for the assessment of in vivo performance in the quest for drug discovery and improved treatment options for IPF patients.
Andrea Nye, President and CEO of East River Bio, stated: “Environment matters. Just as the cell microenvironment matters inside the body, it is also vital for the accuracy of results based on cells grown and studied outside the body. The capacity to conduct more biologically faithful research will enable deeper scientific understanding by providing researchers with the ability to increase high-impact discoveries aimed at improving health outcomes. This grant award further confirms market demand for more accurate and predictive in vitro models while also providing external validation for the potential positive impact that our product is likely to have for scientists in need of native cell microenvironments for improved cell culture models.”
About East River BioSolutions
East River BioSolutions specializes in cell-specific substrates, providing the full, native cell microenvironment essential for the most accurate and actionable results for scientists working in pharmaceutical development, cell biology research and regenerative medicine.